Cartesian Therapeutics, Inc. (RNAC)
8.06
+1.34
(+19.94%)
USD |
NASDAQ |
Dec 09, 10:51
Cartesian Therapeutics Debt to Equity Ratio: -0.3516 for Sept. 30, 2025
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Repligen Corp. | 0.3307 |
| Cabaletta Bio, Inc. | 0.1848 |
| Arcellx, Inc. | 0.1175 |
| NovaBay Pharmaceuticals, Inc. | 0.5936 |
| Palatin Technologies, Inc. | 0.334 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 372.68M |
| Total Liabilities (Quarterly) | 408.52M |
| Shareholders Equity (Quarterly) | -35.84M |
| Current Ratio | 10.67 |
| Net Debt Paydown Yield | -0.16% |